Life-Threatening Proarrhythmia

• To minimize the risk of drug-induced arrhythmia, initiate or reinitiate oral sotalol in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring.
• Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation.
• If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug.
• Calculate creatinine clearance to determine appropriate dosing

Dose Selection, Special Cautions in Renal Impairment

• For detailed instructions regarding dose selection, and special cautions for people with renal impairment, see DOSAGE AND ADMINISTRATION.

Betapace vs Betapace AF

• Sotalol is also indicated for the treatment of life-threatening ventricular arrhythmias and is marketed under the brand name Betapace (sotalol hydrochloride tablets).
• Sotalol AF is not approved for atrial fibrillation or flutter indication
• Do not substitute Betapace (sotalol hydrochloride) for Betapace AF (sotalol hydrochloride AF). Betapace does not have atrial fibrillation indication or package insert information for patient